Extends capabilities in attractive, high-growth medical segments Accelerates portfolio mix shift and path to >20% EBITDA margin target Expected to deliver ~$55 million in run-rate synergies H.B. Fuller Company ("H.B. Fuller" or "the Company") (NYSE:FUL), the world’s largest pureplay adhesives company, today announced it has made a recommended cash offer to acquire Advanced Medical Solutions Group plc ("AMS") (LSE:AMS). "This transaction is a rare opportunity to advance the evolution of our portfolio." said Celeste Mastin, President and CEO of H.B. Fuller. "We have long been clear that medical is a core strategic growth market for H.B. Fuller given its durable demand trends, high reg
Live Feed
Delayed 3mAnalyst · Insider · Buys · SEC · Financials
Signed out · 3-min delay · Sign up for real-time
- H.B. Fuller Announces Offer to Acquire Advanced Medical Solutions
- S&P Upgrades Ratings on Freedom Holding Corp. Subsidiaries to “BB-”
New York, United States, June 25, 2026 (GLOBE NEWSWIRE) -- S&P Global Ratings has upgraded ratings on several subsidiaries of Freedom Holding Corp., a Nasdaq-listed international investment and technology group. The ratings on Freedom Finance JSC, Freedom Finance Europe Ltd., Freedom Finance Global PLC, and Freedom Bank Kazakhstan JSC were raised to "BB-" with stable outlooks. S&P also upgraded the long-term Kazakhstan national scale ratings on Freedom Finance JSC and Freedom Bank Kazakhstan JSC to "kzA-." Earlier, the agency affirmed Kazakhstan’s sovereign credit ratings at "kzAAA" on the national scale and "BBB-" with a positive outlook. Freedom Holding Corp.’s rating remained at "B-" w
- Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update. "Our spin-out, Neurosterix, made great progress during the quarter and are on track to complete the Phase 1 study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, in July," said Tim Dyer, CEO of Addex. "We look forward to seeing the data from the study when available later in the summer." Operating Highlights:
- Large owner Insight Holdings Group, Llc sold $10,198,988 worth of shares (142,311 units at $71.67) (SEC Form 4)
4 - Hinge Health, Inc. (0001673743) (Issuer)
- Large owner Insight Holdings Group, Llc converted options into 870,104 shares and sold $51,634,252 worth of shares (727,793 units at $70.95) (SEC Form 4)
4 - Hinge Health, Inc. (0001673743) (Issuer)
- President and COO Lafargue Rell Q. Jr. was granted 155,318 shares, increasing direct ownership by 34% to 611,254 units (SEC Form 4)
4 - Reservoir Media, Inc. (0001824403) (Issuer)
- Chief Financial Officer Heindlmeyer James A was granted 18,567 shares, increasing direct ownership by 26% to 89,578 units (SEC Form 4)
4 - Reservoir Media, Inc. (0001824403) (Issuer)
- Chief Financial Officer Jin David was granted 400,000 shares, increasing direct ownership by 32% to 1,651,571 units (SEC Form 4)
4 - Fortress Biotech, Inc. (0001429260) (Issuer)
- Director Field Ezra S. was granted 1,231 shares, increasing direct ownership by 0.71% to 175,243 units (SEC Form 4)
4 - Reservoir Media, Inc. (0001824403) (Issuer)
- Director Rothstein Adam was granted 492 shares, increasing direct ownership by 0.62% to 79,376 units (SEC Form 4)
4 - Reservoir Media, Inc. (0001824403) (Issuer)
- Director Glaser Rachel C was granted 8,262 shares, increasing direct ownership by 199% to 12,419 units (SEC Form 4)
4 - COSTAR GROUP, INC. (0001057352) (Issuer)
- Director Berisford John L was granted 8,262 shares, increasing direct ownership by 278% to 11,235 units (SEC Form 4)
4 - COSTAR GROUP, INC. (0001057352) (Issuer)
- Director Hill John W was granted 8,262 shares, increasing direct ownership by 45% to 26,493 units (SEC Form 4)
4 - COSTAR GROUP, INC. (0001057352) (Issuer)
- Director Musslewhite Robert W was granted 8,262 shares, increasing direct ownership by 45% to 26,539 units (SEC Form 4)
4 - COSTAR GROUP, INC. (0001057352) (Issuer)